A combination of chemotherapy and immune-targeting medications may provide long-lasting relief for people with cold agglutinin disease (CAD), though the…
Articles by Marisa Wexler, MS
The oral medication iptacopan — approved for certain blood and complement-related conditions — helped alleviate anemia in most people with…
The results from Annexon Biosciences‘ ongoing proof-of-concept clinical trial of ANX1502, its novel treatment candidate for cold agglutinin…
Establishing a diagnosis of autoimmune hemolytic anemia (AIHA), a group of conditions including cold agglutinin disease (CAD), is sometimes…
Decisions about cold agglutinin disease (CAD) treatment need to be made on a case-by-case basis, considering each patient’s specific…
Obinutuzumab, a B cell-depleting medication approved for certain blood cancers, was effective for controlling primary cold agglutinin disease (CAD)…
Enjaymo (sutimlimab), the only approved treatment for cold agglutinin disease (CAD), needs to be about 80% cheaper or…
A step-by-step process is needed to accurately diagnose cold agglutinin disease (CAD) and other forms of autoimmune hemolytic anemia…
Initial results from a planned proof-of-concept clinical trial testing Annexon Biosciences’ treatment candidate ANX1502 in people with cold…
Apellis Pharmaceuticals and Swedish Orphan Biovitrum (Sobi) have stopped the clinical development of the experimental therapy pegcetacoplan for…